No abstract

No abstract

and David Pryde, focused on reducing attrition through the early assessment of drug safety and brought together a range of international experts from both academia and industry to present the new technologies and their applications in early drug safety assessment.

The pressing challenge pharmaceutical scientists can often be faced with is dealing with drug development candidate molecules with suboptimal drug delivery or pharmaceutical properties. Using the Biopharmaceutical Classification System, analysis of marketed

No abstract